助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   primary efficacy 的翻译结果: 查询用时:0.034秒
图标索引 在分类学科中查询
所有学科
泌尿科学
皮肤病与性病
更多类别查询

图标索引 历史查询
 

primary efficacy
相关语句
  主要疗效
     Results The clearance rate in target warts(primary efficacy) was 71.6% in Solcoderm group , and 77.5% in cryosurgery group(P = 0.451);
     结果主要疗效靶疣体清除率中思可得组为71.6%,冷冻组为77.5%(P=0.451)。
短句来源
     Results: The results showed that the primary efficacy (IIEF Q3+Q4) reached 70.73% after application of the cream.
     结果 :对主要疗效指标 (IIEFQ3+Q4 )的分析结果显示 ,受试者在使用本研究药物后进行性活动时 ,其阴茎勃起程度达到显效和有效者占 70 .73%。
短句来源
     Results: The primary efficacy variables (Questions 3 and 4 from IIEF) revealed a statistically significant( P <0.0001) improvement over placebo with an effective rate of 86% on Viagra vs 37% on placebo.
     结果 :对主要疗效指标 (IIEF问题 3、4)的分析结果显示 ,万艾可对ED病人达到和维持勃起能力的改善作用显著优于安慰剂 (P <0 .0 0 0 1) ,万艾可的临床总有效率为 86 % ,显著高于安慰剂 (37% ) ;
短句来源
     The primary efficacy variables (Questions 3 and 4 from IIEF) revealed a statistically significant ( P < 0.01 ) improvement over placebo along with a clinical efficacy change score with an effective rate of 63.16 % on PGE1 cream vs 9.52 % on placebo.
     结果 :主要疗效评估显示 :使用本研究药物后病人阴茎勃起程度达到显效和有效改善的 ,在乳膏组与安慰剂组分别为 6 3.16 %和 9.5 2 % (P <0 .0 1) ;
短句来源
     The results showed that the primary efficacy variables (Question 3 and 4 from the International Index of Erectile Function IIEF) revealed a statistically significant( P <0.01) improvement on sexual function over placebo,along with a clinical efficacy change score with an effective rate of 55.55% on AUS vs .
     结果主要疗效指标IIEF中问题 3和 4显示 ,AUS对ED患者达到和维持勃起能力的改善作用显著优于安慰剂组 (P <0 .0 1 ) ,AUS总有效率为 5 5 .5 5 % ,显著高于安慰剂组的 2 5 .0 0 % ;
短句来源
更多       
  “primary efficacy”译为未确定词的双语例句
     644 patients(75.9%)were available for the primary efficacy analysis.
     644例患者(75.9%)可接受主要指标分析。
短句来源
     The primary efficacy end points were functional status including favorable functional status (Barthel Index≥95) and obvious dependent survival status (Barthel Index≤60) at 3 months.
     主要有效终点是 3个月时的良好功能状态 (Barthel指数≥95 )及明显依赖生存状态(Barthel指数≤60);
短句来源
     Safety and primary efficacy of recombinant human adenovirus-p53 injection on advanced solid tumor
     重组人p53腺病毒注射液治疗晚期实体肿瘤的安全性和近期疗效评价
短句来源
     Therefore, according to the primary efficacy and attending symptom of HWJND, referring to the research of literature, we mostly study the affection of HWJND to gastric juice of SU's model in rat、 the index of gastric ulceration> the content of GMBF、 PGE_2、 NO and iNOSmRNA in gastric mucosal etc.
     通过和胃降逆方对SU模型大鼠的实验研究,发现和胃降逆方按15、20、25g生药/kg体重给予SU模型大鼠,能减少SU模型大鼠的胃液的分泌量和胃粘膜溃疡指数,增加胃粘膜血流量、前列腺素含量,降低胃粘膜NO含量及其iNOSmRNA表达水平等,结果具有统计学意义(p<0.05-0.01)。
短句来源
     Conclusion: The regression rate of tumor delivered 50 GY is a good index in primary efficacy evaluation and can partly reflect sensitivity of tumor radiotherapy.
     结论:50Gy时肿瘤退缩率是评价近期疗效的较可靠指标,可部分反映肿瘤放射敏感性。
短句来源
更多       
  相似匹配句对
     Efficacy of Felodipine in primary hypertension
     非洛地平对原发性高血压的临床疗效观察
短句来源
     EFFICACY AND SAFETY OF PRAVASTATIN FOR PRIMARY HYPERCHOLESTEROLEMIA
     普伐他丁治疗原发性高胆固醇血症的临床疗效
短句来源
     Primary energy
     一次能源
短句来源
     Will is primary.
     意志是第一性的,理性则是由意志派生出来的,理性命定为意志服务。
短句来源
     On efficacy of law
     论法律实效
短句来源
查询“primary efficacy”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  primary efficacy
Primary efficacy variables were the premenstrual tension scale (PMTS-O) and the clinical global impression of improvement (CGI).
      
Primary efficacy measure was the Investigators' Clinical Global Impression of Change (CGIC).
      
Primary efficacy measures were the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS) and the Physician's Clinical Global Impression of Change.
      
A major problem in evaluating a treatment for fatigue in a randomized controlled trial is the inherent subjectivity of fatigue and the lack of a satisfactory objective quantitative primary efficacy endpoint.
      
The primary efficacy variable was the number of serious infections/subject/year.
      
更多          


The efficacy and safety of Jingmingdan granule as a treatment for the presenile and senile patients with hyperlipidemia and/or hyperlipoproteinemia was investigated in a single blind study. Patients were randomly assigned to treatment with observation group ( n =44, 12g/bag, tid) and control group ( n =44, 1 g/capsule, bid) for 4 weeks. The primary efficacy measures were the total cholesterol in plasma (TC), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), total...

The efficacy and safety of Jingmingdan granule as a treatment for the presenile and senile patients with hyperlipidemia and/or hyperlipoproteinemia was investigated in a single blind study. Patients were randomly assigned to treatment with observation group ( n =44, 12g/bag, tid) and control group ( n =44, 1 g/capsule, bid) for 4 weeks. The primary efficacy measures were the total cholesterol in plasma (TC), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), total glyceride (TG). After treatment, TC, LDL, and TG were sig_ nificantly gone down in the observation group compared with them before treatment and were significanty different from the control group. Among them TG's reduction was the most significant, reaching 61.50%. HDL was also significantly increased. At the same time arteriosclerostic indexes were significantly reduced, compared with them before treatment. The apparent efficacy of the observation group is 79.55%, much better than the control group, and the apparent efficacy of the presenile group (46~59 year old) higher than senile group (60~79 year old). Side effect was not found in the observation. In contrast, Jingmingdan granule was significantly protective against liver dysfunction in the patients. These data suggest that Jingmingdan granule is a well tolerated drug which can reduce TC, TG and LDL and increase HDL. It also has a protective effect on liver function in patients with hyperlipidemia or hyperlipoproteinemia.

单盲对照试验观察精明丹冲剂治疗老年及老年前期高脂血症的疗效和安全性。 88例患者被随机分为精明丹冲剂观察组和月见草油胶丸对照组。结果显示 ,观察组胆固醇 (TC)、甘油三酯(TG)、低密度脂蛋白胆固醇 (LDL c)水平较治疗前均非常显著地降低 ,其中TG含量比给药前下降达 61 5 %。同时 ,高密度脂蛋白胆固醇 (HDL c)水平显著增高 ,动脉硬化指数 (AS)也显著下降。治疗显效率为 79 5 5 % ,总有效率为 10 0 % ,其中老年前期的治疗显效率高于老年期。服药后未见毒副反应 ,且对肝功能异常者反有显著降低谷丙转氨酶的效果。部分病例 1年后随访无复发。提示精明丹冲剂益气活血、利水化痰 ,对老年及老年前期高脂血症患者具有非常显著的降脂和调整血脂代谢及保护肝功能的作用

Objective:To study the efficacy of cerivastatin in treatment of hypercholesterolaemia. Methods:After a 5 weeks singleblind runin period (Period A),470 patients were randomised to receive cerivastatin 0.1 mg(n=119),0.2 mg (n=117),0.3 mg(n=116) or placebo(n=118),once daily at bedtime for 8 weeks(Period B).At the end of Period B,patients with a lowdensity lipoprotein cholesterol decrease of ≥20% from baseline continued to receive their randomised dose of cerivastatin or placebo for a further 16 weeks,for an extended...

Objective:To study the efficacy of cerivastatin in treatment of hypercholesterolaemia. Methods:After a 5 weeks singleblind runin period (Period A),470 patients were randomised to receive cerivastatin 0.1 mg(n=119),0.2 mg (n=117),0.3 mg(n=116) or placebo(n=118),once daily at bedtime for 8 weeks(Period B).At the end of Period B,patients with a lowdensity lipoprotein cholesterol decrease of ≥20% from baseline continued to receive their randomised dose of cerivastatin or placebo for a further 16 weeks,for an extended assessment of safety.Results:Mean percentage change in lowdensity lipoprotein cholesterol from baseline to the end of Period B in the perprotocol population (the primary efficacy parameter)was -(21.5±13.1)% in the 0.1 mg group,-(25.8±13.0)% in the 0.2 mg group and -(29.5±20.5)% in the 0.3 mg group,compared with a (0.7±13.0)% increase in the placebo group(P=0.0001 for all doses versus placcbo).Conclusion:Cerivastatin was found to have a good efficacy and safety profile in the Chinese hypercholesterolaemic population studied.

目的 :探讨西立伐他汀治疗原发性高胆固醇血症的有效性及安全性。方法 :分为 3个阶段 ,第一阶段(A阶段 )为 5周的单盲进入阶段 ,第二阶段 (B阶段 )为期 8周 ,将 470例患者随机分为 0 .1mg组 ( 119例 )、0 .2mg组 ( 117例 )、0 .3mg( 116例 )和安慰剂组 ( 118例 ) ,均为 qd ,睡前服用。B阶段结束时 ,LDL C水平较试验前降低≥2 0 %者 ,继续B阶段治疗 (西立伐他汀或安慰剂 ) 16周 (C阶段 ) ,以延长安全性的评价时间。结果 :西立伐他汀各组的LDL C降低百分数分别为 ( 2 1.5± 31.1) % ( 0 .1mg组 ) ,( 2 5 .8± 13.0 ) % ( 0 .2mg组 )和 ( 2 9.5± 2 0 .5 ) % ( 0 .3mg组 ) ,安慰剂组的LDL C较试验前升高 ( 0 .7± 13 .0 ) % ,与各用药组相比 ,P值均为 0 .0 0 0 1。结论 :西立伐他汀治疗高胆固醇血症安全有效

s: Objectives: To evaluate the efficacy and safety of Viagra on men with ED of various etiologies. Methods: This study was a double blind, randomized (placebo:Viagra,1:3), placebo controlled, flexible dose study of Viagra oral tablets(25, 50 and 100mg) taken over 8 weeks. A total of 84 subjects were screened and randomized. Results: The primary efficacy variables (Questions 3 and 4 from IIEF) revealed a statistically significant( P <0.0001) improvement over placebo with an effective rate of 86%...

s: Objectives: To evaluate the efficacy and safety of Viagra on men with ED of various etiologies. Methods: This study was a double blind, randomized (placebo:Viagra,1:3), placebo controlled, flexible dose study of Viagra oral tablets(25, 50 and 100mg) taken over 8 weeks. A total of 84 subjects were screened and randomized. Results: The primary efficacy variables (Questions 3 and 4 from IIEF) revealed a statistically significant( P <0.0001) improvement over placebo with an effective rate of 86% on Viagra vs 37% on placebo. The secondary efficacy variables supported the conclusion of the primary efficacy variables and included the remaining 13 IIEF questions,event log data(assessing the proportion of successful attempts at sexual intercourse, 71.8% on Viagra vs 17.0% on placebo), and the global assessment question(treatment had improved their erections,87.3% on Viagra vs 36.8% on placebo) .Viagra was well tolerated.The incidence of adverse events was higher for Viagra(33.3%) than for placebo(19.0%). Conclusions: Oral Viagra is an effective, well tolerated treatment for various erectile dysfunction.

目的 :评估万艾可 (Viagra○R)治疗男性勃起功能障碍 (ED)的有效性和安全性。 方法 :本试验为双盲、随机(安慰剂 :西地那非 ,1:3)、安慰剂对照、剂量可调整 (2 5、5 0和 10 0mg)、持续 12周的临床研究。共有 84名受试者参与本研究。 结果 :对主要疗效指标 (IIEF问题 3、4)的分析结果显示 ,万艾可对ED病人达到和维持勃起能力的改善作用显著优于安慰剂 (P <0 .0 0 0 1) ,万艾可的临床总有效率为 86 % ,显著高于安慰剂 (37% ) ;对心理性、器质性和混合性ED的有效率分别为 83%、79%和 81% (安慰剂组分别为 5 0 %、33%和 30 % )。同时 ,对次要疗效指标评估 (IIEF其余 13个问题、记事表和总评题 )亦显示 ,万艾可改善性生活的作用明显优于安慰剂 ;万艾可组性交成功率平均为71.8% ,显著高于安慰剂组 (17.0 % ) ;有 87.3%的万艾可组受试者认为研究药物改善了其勃起功能 ,显著高于安慰剂组 (36 .8% )。无 1名受试者因不良事件而中断研究 ,万艾可组的不良事件发生率 (33.3% )较安慰剂组高(19.0 ...

目的 :评估万艾可 (Viagra○R)治疗男性勃起功能障碍 (ED)的有效性和安全性。 方法 :本试验为双盲、随机(安慰剂 :西地那非 ,1:3)、安慰剂对照、剂量可调整 (2 5、5 0和 10 0mg)、持续 12周的临床研究。共有 84名受试者参与本研究。 结果 :对主要疗效指标 (IIEF问题 3、4)的分析结果显示 ,万艾可对ED病人达到和维持勃起能力的改善作用显著优于安慰剂 (P <0 .0 0 0 1) ,万艾可的临床总有效率为 86 % ,显著高于安慰剂 (37% ) ;对心理性、器质性和混合性ED的有效率分别为 83%、79%和 81% (安慰剂组分别为 5 0 %、33%和 30 % )。同时 ,对次要疗效指标评估 (IIEF其余 13个问题、记事表和总评题 )亦显示 ,万艾可改善性生活的作用明显优于安慰剂 ;万艾可组性交成功率平均为71.8% ,显著高于安慰剂组 (17.0 % ) ;有 87.3%的万艾可组受试者认为研究药物改善了其勃起功能 ,显著高于安慰剂组 (36 .8% )。无 1名受试者因不良事件而中断研究 ,万艾可组的不良事件发生率 (33.3% )较安慰剂组高(19.0 % ) ,但绝大多数为轻度、一过性的。 结论 :口服万艾可是一种可治疗各种病因导致的勃起功能障碍安全有效的药物 ,按需服用时能很好耐受。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关primary efficacy的内容
在知识搜索中查有关primary efficacy的内容
在数字搜索中查有关primary efficacy的内容
在概念知识元中查有关primary efficacy的内容
在学术趋势中查有关primary efficacy的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社